Nautilus Biotechnology, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $41.1M | $50.5M | $47.3M | $37.7M | $29.4M |
| Operating expenses | $66.8M | $81.5M | $76.2M | $63.6M | $50.5M |
| Income tax expense | $0 | $0 | $0 | $0 | $0 |
| Net income | -$59.0M | -$70.8M | -$63.7M | -$57.9M | -$50.3M |
| Balance Sheet | |||||
| Cash and equivalents | $12.4M | $27.6M | $19.4M | $114.5M | $185.6M |
| Current assets | $106.0M | $132.8M | $176.8M | $187.2M | $349.2M |
| Total assets | $191.1M | $242.7M | $305.6M | $350.1M | $398.4M |
| Current liabilities | $8.0M | $7.6M | $9.1M | $6.8M | $5.8M |
| Total liabilities | $34.1M | $34.0M | $40.2M | $35.1M | $34.9M |
| Stockholders' equity | $157.0M | $208.7M | $265.4M | $314.9M | $363.6M |
| Cash Flow Statement | |||||
| Cash from operations | -$50.7M | -$59.1M | -$51.7M | -$45.8M | -$39.2M |
| Depreciation and amortization | $1.7M | $2.0M | $1.8M | $1.2M | $1.0M |
| Stock-based compensation | $6.8M | $12.7M | $12.1M | $10.4M | $7.9M |
| Capital expenditure | $1.3M | $2.1M | $2.4M | $2.3M | $2.3M |
| Free cash flow | -$52.0M | -$61.3M | -$54.2M | -$48.1M | -$41.5M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 127.1M · Free float 15.1%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.